Other Novo Nordisk and OpenAI forge alliance to drive speedy drug development Pharmaceutical TechnologyNovo Nordisk inks this deal with OpenAI as the total value of AI partnerships took a 120% YoY uptick between 2024 and 2025.OtherRead full story pharminent April 14, 2026 (Last updated: April 14, 2026) Pharmaceutical Technology Novo Nordisk inks this deal with OpenAI as the total value of AI partnerships took a 120% YoY uptick between 2024 and 2025. OtherRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Revolution rockets on strong pancreatic cancer dataNext: Travere claims first FDA OK in rare kidney disease FSGS Related Stories Other ASCO ’26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer pharminent June 2, 2026 Other ASCO26: Symptom-tracking app helps advanced cancer patients pharminent June 2, 2026 Other All eyes on Revolution, bispecific antibodies and more at ASCO26 pharminent May 26, 2026
